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ABSTRACT
INVESTIGATING THE PROTECTIVE EFFECTS OF INTESTINAL GABAA RECEPTOR ACTIVATION
ON AN ANIMAL MODEL OF MULTIPLE SCLEROSIS
By Hannah M. Kohl
Spring 2021
Gamma aminobutyric acid (GABA) is an inhibitory neurotransmitter, produced by
neurons in the central nervous system (CNS) and by some species of intestinal bacteria.
GABAA receptors are found not only in the CNS, but also in T cells and within the
intestines. Past studies have indicated that GABA can have an anti-inflammatory effect
and production of GABA by gut bacteria decreases in patients with multiple sclerosis
(MS). We examined whether administration of a positive allosteric GABAA receptor
modulator, farnesol, ameliorates the progression of experimental autoimmune
encephalomyelitis (EAE), a murine model of MS and whether those effects correlated
with a decrease in immune cell infiltration of the central nervous system. We observed a
significant treatment effect on clinical scores, as well as immune cell infiltration. Seeking
to determine if these effects were due to GABAA receptor activation or other antiinflammatory effects of farnesol, we investigated whether modifying mice microbiota
with GABA-producing bacteria influences EAE severity. We used a Lactococcus lactis
strain (P8 GAD-L. lactis) genetically modified with an extra copy of glutamic acid
decarboxylase (GAD) and glutamic acid/glutamate antiporter to produce high levels of
GABA (Castillo, unpublished data). P8 GAD-L.lactis produced significantly more GABA
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than the L. lactis control strain (pAC-L. lactis). EAE-induced C57BL/6 mice treated with
P8 GAD-L. lactis (n=10) had significantly lower clinical scores than the sham control
group (autoclaved media; n=10) and the L. lactis control group (pAC-L.lactis; n=10).
Despite trying, we were unable to repeat this experiment due to difficulties inducing
disease. We farther tested different C57BL/6 mouse providers (Envigo and Jackson
Laboratory) to determine if the decrease in disease severity resulted from the provider
(Envigo). The Envigo group (n=10) had fewer animals die from severe EAE compared to
the Jackson group (n=10), but it wasn’t significant. More experiments are needed to
determine what may be causing this difference in disease severity and if oral treatment
with a GABA producing probiotic protects against mouse EAE.
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INTRODUCTION
Multiple Sclerosis (MS)
MS is a major health concern affecting millions of people. It is the most common
reason for non-traumatic disability in adults from developed nations. Nearly a million
people in the United States have MS, with the northern states having the greatest
prevalence (Wallin et al., 2019). Multiple sclerosis (MS) is a neurodegenerative disease
characterized by inflammatory lesions of the central nervous system (CNS) that lead to
demyelination of neurons. As the myelin sheath, the insulating layer around nerves, is
damaged sclerosed plaques develop. These sclerosed plaques are where the disease
gets its name (Dobson and Giovannoni, 2019). As the damage increases, neurons are
unable to efficiently send electrical signals. Disruption of neuronal signaling leads to a
wide variety of neurological symptoms such as vision problems, depression, fatigue,
dizziness, and paralysis (Trapp et al., 1998; Thompson et al., 2018) and can ultimately
lead to death (Scalfari et al., 2013). Symptoms can vary drastically between individuals.
MS is categorized by the progression of neurological decline in patients.
Relapsing/remitting MS (RRMS) is the most common form. RRMS is categorized by
periods of remission followed by relapses where neurological symptoms worsen. About
85% of newly diagnosed MS patients are diagnosed with RRMS. Ten to fifteen years
following diagnosis, 50% of those patients will develop secondary progressive MS
(SPMS), where neurological symptoms gradually worsen with few if any remissions.
Around 15% of newly diagnosed patients are diagnosed with primary progressive MS
(PPMS) where neurological symptoms gradually worsen with few remissions (De Angelis

et al., 2018). MS can be difficult to diagnose due to varying symptoms that often
resemble other diseases. An MRI scan can identify brain damage, but MS lesions can
look like damage caused by other diseases and trauma. To diagnose, doctors look for
brain damage occurring in multiple locations at differing times, where other diagnoses
have been ruled out (Miki, 2019). Multiple MRI scans are often required.
The inflammatory lesions of MS are caused by immune cells infiltrating the CNS
and attacking the myelin sheath. Both innate and adaptive immune systems and their
associated cells contribute to MS disease pathology. The innate immune system is the
body’s first line of defense against pathogens and injury; it is non-specific and deploys
rapidly. Cells of the innate immune system include natural killer cells (NK cells),
macrophages, neutrophils, dendritic cells, mast cells, basophils, and eosinophils. It is
also responsible for activating the adaptive immune system. The adaptive immune
system is the body’s second line of defense. It requires activation, is antigen specific, and
retains memory through memory T and B lymphocytes. The cells of the adaptive
immune system are T and B lymphocytes.
Immune cells and signaling molecules that play a role in MS
Monocytes are phagocytes that ingest pathogens and dead or damaged cells.
They are derived from granulocyte -macrophage progenitor cells and can in turn
differentiate into antigen presenting cells (APCs) such as macrophages and dendritic cells
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(DCs). These cells can be farther differentiated based on their location, function, and cell
origin. Microglia are the resident macrophages of the CNS and reside in the parenchyma.
Activation and infiltration of the CNS by microglia and other macrophages
contribute to the pathology of MS. Microglia and infiltrating macrophages are the main
immune cells found near damaged axons (Trapp et al., 1998) and within CNS lesions in
MS (Hemmer et al., 2015). Activated microglia and macrophages can secrete proinflammatory molecules such as interleukin 1 beta (IL-1β), tumor necrosis factor alpha
(TNF-α), and interleukin 6 (IL-6) (Cavaillon, 1994; Hanisch, 2002) increasing neuronal
inflammation and the process of demyelination. Macrophages remove dead or
degenerate myelin and may be one of the main contributors to myelin damage in early
MS lesions (Henderson et al., 2009).
T and B lymphocytes (T cells and B cells, respectively) also play a critical role in
MS pathology. As part of the adaptive immune system, T cells are activated by antigenpresenting cells (APCs) presenting small peptides derived from processed antigens to
them. T cells mature in the thymus and B cells mature in the bone marrow. B cells are
able to be activated by unprocessed antigens and with help provided by T cells
differentiate into plasma cells, which are responsible for producing antibodies. B cells
are often found in early MS lesions. Some studies find antibodies against myelin in
cerebral spinal fluid of some MS patients, but this result is inconsistent among all studies
conducted (Karni et al., 1999; Reindl et al., 1999; Kennel De March et al., 2003; Khalil et
al., 2006; Wekerle, 2017). In childhood onset MS, it has been theorized that certain
antibodies found in patients, such as anti-myelin oligodendrocyte glycoprotein (MOG),
3

are one of the reasons for a different disease phenotype in children (Bar-Or et al., 2016).
In addition, drugs targeting B cells, such as rituximab, have been used to successfully
treat MS. This is consistent with a role for B cells in the pathology of MS.
T cells are one of the main drivers of MS pathology (Bhat and Steinman, 2009). T
cells can be divided into two main groups CD4+ cells (Helper T cells and Regulatory T
cells) and CD8+ cells (Cytotoxic T cells) both of which are involved in MS. The CD4+ and
CD8+ refer to the expression of coreceptors (CD4 or CD8) on their cell surfaces, serving
as essential markers for the phenotypic analysis of the cells by immunological methods,
such as flow cytometry. Activated CD8+ T cells that function to directly destroy infected
or damaged host cells, they are often found in MS lesions and have been shown to be
capable of killing neuronal cells (Huseby et al., 2012). Activated CD4+ T cells differentiate
into T helper cell (Th cells) subsets that depending on their nature release specific
cytokines, small messenger proteins, that help coordinate immune responses. One
specific subset of CD4+ Th cells are the T regulatory cells (Tregs), that help develop selftolerance by controlling the proliferation of inflammatory cell subsets. Dysfunction in
Tregs have been linked to increased MS disease severity (Danikowski et al., 2017).
Differentiated Th cells are classified depending on the type of cytokines they
produce. Some produce inflammatory cytokines (such as IL-17A, GM-CSF, IFN-γ, TFN-α)
and others anti-inflammatory cytokines (such as IL-10, IFN-1α, IFN-1β). Some categories
of Th cells are associated with MS more than others. Specifically, Th17 CD4+ cells that
produce interleukin 17A (IL-17A) which is a critical recruiter of inflammatory cells such
as neutrophils, macrophages, and cytotoxic cells. Many of them also produce a cytokine
4

called granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF exacerbates
the differentiation of CD4+ T cells into Th17 CD4+ T cells. The two cytokines are involved
in a positive-feedback loop that increases inflammation and subsequent tissue damage
causing demyelination and ultimately paralysis. Increased levels of these cytokines are
associated with the disease pathology of MS, as observed in patients (Milosevic et al.,
2015). Experimental evidence also suggests their role in pathogenesis. Mice who were
genetically engineered to have no production of GM-CSF cytokines are resistant to
induction of Experimental Autoimmune Encephalomyelitis (EAE), an animal model that
resembles human MS (Ponomarev et al., 2007). The lack of IL-17A also significantly
ameliorates the EAE (Komiyama et al., 2006).
Dysregulation of calcium has also been linked to a number of neurodegenerative
disorders, including MS (Kattimani and Veerappa, 2018; Verma et al., 2018). Calcium is a
major intracellular signaling molecule responsible for regulating numerous cellular
processes such as muscle contraction and neurotransmitter release (Enders et al., 2020).
Calcium is also responsible for oligodendrocyte (the cells that form the myelin sheath)
maturation and myelin sheath formation (Cheli et al., 2015; Enders et al., 2020).
Extracellular calcium also directs microglia migration to brain lesions (Tvrdik and Kalani,
2017), such as found in MS. Dysregulation of calcium can lead to excitotoxicity, where
an overload of intracellular calcium causes apoptosis (cell death) (Rajda et al., 2017;
Verma et al., 2018). Some inflammatory cytokines such as tumor necrosis factor α (TNFα) increase calcium levels and activated T cells can also increase intracellular calcium
levels (Enders et al., 2020).
5

Etiology of MS
The cause of MS is still uncertain. From 1990 to 2015, there was a 59% increase
in global MS rates (Wilkins, 2019). There does seem to be a genetic component to the
disease, as some people have a higher susceptibility to it. The first discovered and
strongest genetic factor linked to MS are variants of the human leukocyte antigen
region (HLA) locus, that codes for the highly polymorphic cell-surface glycoproteins
which are key components of the immune system. Other genetic variants associated
with MS include genes implicated in T-cell activation and expansion, cellular
recruitment, escape from regulatory immune surveillance, and various other immune
functions. Epigenetic changes may also play a role as some of the genes, differentially
expressed in MS patients compared to controls, have been shown to be partially
controlled by epigenetic factors; such as promoter methylation (Muñoz-Culla et al.,
2013).
Genetics are not the only risk factor involved in MS. There is some evidence that
it is associated with Epstein–Barr virus (EBV) infection. However, the association is
indirect and might not correspond with a direct link, as 90% of Americans have been
infected with the virus by the age of 20 (Guan et al., 2019). An infection with EBV seems
to increase the risk of developing MS, as almost all MS patients have had the virus.
Having an active infection increases the risk substantially (Ascherio and Munger, 2007)
and increased quantities of EBV specific antibodies are associated with a heightened risk
of developing MS (Lucas et al., 2011).
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Other factors that increase the risk of MS are living at higher latitudes specifically
during the formative childhood years. This may be due to a lack of vitamin D (Sintzel et
al., 2017). There is also a significant gender difference in MS. Females are three times
more likely to get MS than men. Yet, this has not always been the case. The incident rate
of females getting MS has been increasing over the years (Voskuhl, 2020), which may
imply lifestyle changes due to culture. Though males are less likely to get MS, those who
do often have a worse prognosis and faster progression than females (Voskuhl, 2020).
MS is more common in developed nations, particularly those in Northern Europe and
North America (Browne et al., 2014), this may partially be due to an increase in the
availability of medical care and reporting. Other variables that seem to be involved
include diet, exercise, infectious disease, host microbiota, stress, and age (Joscelyn and
Kasper, 2014).
Current MS treatments
There is currently no cure for MS. Of the treatments currently available, many are
expensive, and they are not always effective and are associated with a wide array of side
effects. Many of the current treatments focus on weakening the immune system to
reduce inflammation. Often the treatment’s effectiveness wanes over time requiring
replacement with a more powerful drug as the disease worsens. In addition, some
treatments have been associated with increased risk of infections. PML (Progressive
Multifocal Leukoencephalopathy) is a dangerous disease of the brain caused by the John
Cunningham virus. This disease is associated with some of the more aggressive MS
treatment with anti-VLA-4 due to their weaking of the immune responses in the CNS.
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An alternative treatment is the use of anti-inflammatory cytokines to decrease
inflammation in the CNS. Type-I interferon beta-1α and 1β (INF-1α and INF-1β) are used
as anti-inflammatory treatment in MS patients. This option has fewer side effects but is
not effective for all patients. Other drugs directly target immune cells for destruction,
reducing the ability of the immune system to exacerbate disease. The MS drugs
Alemtuzumab, Ocrelizumab, and Natalizumab are all monoclonal antibodies that target
immune cells. Hematopoietic stem cell transplantation (HSCT), where a patient’s
immune cells are all destroyed by chemotherapy and then replaced with bone marrow
hematopoietic stem cells, is another possible treatment. These more aggressive
treatments are often more effective than cytokine-based approaches, but also have
more serious side effects (table 1). Side effects like PML (progressive multifocal
leukonencephalopathy), a dangerous disease of the brain caused by the John
Cunningham virus. Because of the lack of a completely effective and safe treatment, the
search for a new therapeutic alternative must continue as it is an unmet clinical need.
Intestinal Microbiota
The microbiota refers to the sum of all microorganisms within a defined
environment (Marchesi and Ravel, 2015). Increasingly studies have shown a link
between intestinal microbes and MS. The human intestinal microbiota contains 10-100
trillion microorganisms (Gill et al., 2006). It is needed for the appropriate development
of the immune system (Kiyono et al., 1982; Wannemuehler et al., 1982; Sudo et al.,
1997), and altered compositions, named dysbiosis, has been associated with several
inflammatory disorders, including MS (Ochoa-Repáraz et al., 2018; Kohl et al., 2020).
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Germ free mice (born and raised without microbiota) show an altered immune cell
balance between pro- and anti-inflammatory cells when compared to those raised with
a normal intestinal microbiota (Olszak et al., 2012) that makes them less susceptible to
different inflammatory-mediated diseases. The intestinal microbiome is markedly
malleable, changing in response to, for example, diet, age, weight, and environment.
This makes it a great target for therapeutic change. Many of the factors that seem to be
involved in increased risk of MS are known to affect the gut microbiota as well (OchoaRepáraz and Kasper, 2014).
Mice orally treated with broad-spectrum antibiotics to reduce their gut
microbiota had significantly lower EAE disease severity, compared to untreated controls,
or mice that were treated with an intraperitoneal antibiotic that didn’t affect the gut
microbiota (Ochoa-Repáraz et al., 2009). The treatment with oral antibiotics is
protective only when administered at early stages of the disease, when the
inflammatory process is most prominent (Colpitts et al., 2017). Germ free mice develop
EAE at a severely attenuated rate, have significantly reduced symptoms, and the
number of pro-inflammatory cytokines associated with EAE pathology is reduced in
comparison to mice colonized with a complete microbiota (Lee et al., 2011).
MS patients have a different microbiota population compared to healthy
individuals (Cekanaviciute et al., 2017). Microbiota from MS patients transplanted into a
transgenic mouse model of spontaneous brain autoimmunity, leads to a significantly
higher incidence of autoimmunity than that which occurs from their healthy twin’s
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microbiota being transplanted (Berer et al., 2017). Fecal transplants from healthy
individuals given to MS patients seem to decrease some of the neurological symptoms
of their disease (Evrensel and Ceylan, 2016). Studies continue to come out showing a
link between EAE or MS severity and gut microbiota composition.
Changes in the intestinal microbiota can lead to increased inflammation, in a
process defined as dysbiosis. Intestinal inflammation has been associated with increased
intestinal permeability, while increased intestinal permeability can lead to an increase in
microbial translocation and entry of microbial components such as Gram-negative
lipopolysaccharide (LPS, or endotoxin) to the lamina propria, resulting in an increase in
systemic inflammation (Sánchez de Medina et al., 2014). Ten months after injection with
LPS mice still had elevated brain levels of tumor necrosis factor-alpha (TNF-a) (Qin et al.,
2007). TNF-a is a pro-inflammatory cytokine that is also found in elevated levels in MS
brains and circulation. Patients with MS have increased intestinal permeability (Yacyshyn
et al., 1996). Increased intestinal permeability, sometimes called leaky gut, has been
reported at the onset of EAE in mice (Nouri et al., 2014). Furthermore, EAE severity is
associated with corresponding increases in intestinal permeability (Secher et al., 2017).
Certain types of bacteria, such as Bacteroides fragilis, help to ameliorate the effects of
increased intestinal permeability (Hsiao et al., 2013), while other species exasperate it
(Wilson et al., 2018). Germ free mice have been found to have fewer tight junction
proteins, occludin and claudin-5 (Braniste et al., 2014), this results in more leaky
epithelia, as tight junctions are what holds the epithelia cells tightly together preventing
leakage. Tight junctions are involved in both increased permeability in the gut and in the
10

blood brain barrier (Braniste et al., 2014). One of the earliest symptoms of MS is
increased blood brain barrier permeability and infiltration of lymphocytes and immune
cells (Ortiz et al., 2014).
γ-Aminobutyric acid (GABA)
GABA is the principal inhibitory neurotransmitter in the CNS (Wong et al., 2003).
Low GABA levels are associated with numerous neurological diseases, such as
schizophrenia (Geffen et al., 2009), Huntington’s disease (Garret et al., 2018), and
epilepsy (Treiman, 2001), and MS(Cawley et al., 2015; Yalçınkaya et al., 2016). In
addition to being produced by neurons in the CNS, certain intestinal bacteria such as
Lactococcus lactis (Nomura et al., 1999) and Lactobacillus produce GABA by
decarboxylating glutamate, through the enzymatic action of glutamic acid decarboxylase
(Dhakal et al., 2012). It is also found in many fermented foods because lactic acid
bacteria produce it (Dhakal et al., 2012).
There are 2 known types of GABA receptors which activate when bound to GABA;
GABAA receptor and GABAB receptor. Originally, there were thought to be 3 types of
GABA receptors with GABAC receptors being the third type. Additional research revealed
that GABAc receptors are really a subtype of GABAA receptors (Martin et al., 2020).
GABAA receptors were the first to be characterized and are well researched, due to their
ability to bind with numerous pharmacological agents (Olsen and DeLorey, 1999). They
are large pentameric transmembrane, chloride gated ion channel receptors (Chebib and
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Johnston, 1999). GABAB receptors in contrast are metabotropic G protein binding
receptors. Both types of receptors are widespread in the CNS (Martin et al., 2020).
In addition to their expression in the cells of the neuronal system, GABAAR are
also expressed in immune cells. More importantly, targeting GABAAR promote
significant functional changes in immune cells. T cell’s express GABAAR (Mendu et al.,
2012) and activation of those receptors inhibited antigen specific T cell proliferation
(Tian et al., 1999). GABA has been shown to inhibit T cell activation cascades and
decrease pro-inflammatory T cell responses without causing apoptosis and thereby
immune deficiencies (Tian et al., 2004). As T cells are a major disease-driving mechanism
in MS and murine EAE (Bhat and Steinman, 2009), this may be a mechanism for GABA
effecting MS and EAE severity. Oral administration of homotaurine, which activates
GABAA receptors, ameliorates EAE symptoms in mice (Tian et al., 2018). In the same
study, researchers looked at the effect of the activation of GABAAR on cytokine
production and found that it decreases the amount of proinflammatory cytokines (IFN-y
and IL-17A) and increases the quantities of anti-inflammatory cytokines (IL-10) in EAE
mice.
In addition, the oral treatment with Lactic acid producing bacteria (LABs) which
produce intestinal GABA appear to be helpful in decreasing inflammation (Lavasani et
al., 2010). Mice who received an oral dose of Lactobacillus had an increase in GABA
levels in their brains (Janik et al., 2016), showing that increased intestinal GABA can
impact brain GABA levels.
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Activation of GABAAR in the gut could also affect the vagus nerve function (Auteri
et al., 2015), as a mechanism linking the gut and the brain. The vagus nerve is the main
nerve of the parasympathetic branch of the automatic nervous system (ANS), and
regulates homeostasis, metabolism, and immune responses. Direct stimulation of the
peripheral vagus nerve in vivo in rats induced with endotoxemia; inhibited TNF synthesis
in liver, attenuated peak serum TNF amounts, and prevented the development of shock
(Borovikova et al., 2000). Stimulation of the vagus nerve can also and increase
production of GABA in the brain (Van Leusden et al., 2015). Chronic oral treatment of L.
rhamnosus, a GABA producer, results in increased GABA production in the brain of mice
in a vagus nerve-dependent mechanism. This is evidenced by the cessation of that GABA
production when the vagus nerve was severed via subdiaphragmatic vagotomy (Bravo
et al., 2011).
Recent evidence suggest that intestinal GABA plays a role maintaining the
integrity of the intestinal barrier, possibly disrupted in the context of inflammatory
diseases, as indicated above. In a study by Sokovic et al. (2019), supernatants containing
GABA (and other supernatants without GABA as controls) were administered in vitro to
intestinal epithelial cells previously exposed to IL-1b, a proinflammatory cytokine. The
supernatants that contained GABA had a greater protective effect on intestinal integrity
compared to ones without GABA, increasing the expression levels of zonulin, occludin
and claudin 4, proteins involved in epithelial tight junctions (Sokovic Bajic et al., 2019).
It has been found that in EAE mice the amount of intestinal microbe GABA
producers decreases in the early stages of the disease. In a study, by our lab (Colpitts et
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al., 2017), we looked at the relative abundances of Lactobacilli after EAE was induced.
There was a clear decrease in Lactobacilli numbers in the early stage of the disease, days
9-14. Previous data from our lab showed a significant decrease in clinical scores for EAE
mice that were given an unmodified Lactococcus lactis, which produces GABA, as a
treatment in comparison to controls.
Farnesol
Farnesol is a positive allosteric modulator of GABAA receptors (Jeevan et al.,
2019). Farnesol (FOL) is a 15-carbon acyclic sesquiterpene primary alcohol. It is
commonly found as essential oil in plants (Jung et al., 2018). Oral administration of FOL
has been shown to have powerful anti-oxidant and anti-inflammatory effects in mice
(Jahangir et al., 2005; Ku and Lin, 2015). FOL has been shown to protect against an LPSinduced murine model of neurodegeneration (Santhanasabapathy and Sudhandiran,
2015), as well as an acrylamide-induced model of neurotoxicity (Santhanasabapathy et
al., 2015). Farnesol is known to block Ca2+ channels (Luft et al., 1999; Beedle and
Zamponi, 2000), which may help protect against intraneuronal Ca2+ overload in MS.
Farnesol impacts the microbiota. It is an important quorum sensing molecule.
Microbes use quorum sensing molecules to communicate between cells to detect and
respond to cell density. Biofilms are often formed when a certain cell population density
is detected. Biofilms can reduce the effectiveness of immune cells, such as neutrophils
and macrophages, and some bacteria begin to produce inflammatory molecules after
forming a biofilm (Watters et al., 2016). FOL has been shown to inhibit the formation of
biofilm in certain species of inflammatory pathogenic gut flora such as Candida albicans
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(Ramage et al., 2002) and methicillin-resistant Staphylococcus aureus (MRSA) (Jabra-Rizk
et al., 2006). While Lactobacillus subtilis biofilm formation, which has been shown to
promote stress resistance, life extension, and protect against pathogenic infection in C.
elegans (Smolentseva et al., 2017), is promoted by farnesol (Feng et al., 2014). Like
GABA, FOL also strengthens epithelial integrity by increasing epithelial cell occludin
expression. It also increases transepithelial electrical resistance and reduces paracellular
flux (Fang et al., 2019).
Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of MS
One of the most common animal models for MS is experimental autoimmune
encephalomyelitis (EAE). This model has been used to study MS for over 100 years, its
origins are linked to the encephalomyelitis originally observed in Louis Pasteur’s rabies
vaccine in the 19th century (Farooqi, Gran, & Constantinescu, 2010). When animals
were injected with a spinal cord emulsion containing a weakened rabies virus to protect
against rabies some of them developed CNS inflammation and paralysis symptoms
despite not having rabies. Since then, EAE has been developed in primates, mice, and
other mammals (Burrows et al., 2019). Due to its extensive use and ease, it works well
for comparing treatments.
EAE induction can be either active or passive. In passive EAE induction,
encephalitogenic T cells are isolated from the lymphoid tissues of animals already
immunized with myelin antigen. These T cells are specific to myelin antigen and when
transferred to naïve recipients attack the myelin sheath and start the disease. In active
EAE induction, T-cell mediated immunity is induced by injection of myelin antigens (such
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as, myelin oligodendrocyte glycoprotein peptides 35-55, or MOG35-55)(Burrows et al.,
2019). In either case myelin specific CD4+ T cells cross the blood brain barrier into the
CNS parenchyma. APCs activate them by presenting myelin peptides. Activation of T
cells lead to a pro-inflammatory cascade mediated by cytokines. Continuous
inflammation results in myelin sheath damage and eventual paralysis.
There are a few major differences between MS and EAE. While MS develops
spontaneously, EAE requires an active sensitization of the immune system through
exposure to CNS antigens. The exception being spontaneous EAE, which still requires
special transgenic animals (Gold et al., 2006; Burrows et al., 2019). EAE also requires a
strong immune adjuvant to boost the immune response, which is unlikely to occur in
natural MS development even with infections. These differences may result in
differences in how the T cells and other immune cells activate and attack, resulting in
differing outcomes between various therapeutics in EAE model animals and real MS
patients. Currently, not enough is known about the induction of MS to enable an exact
repeat in an animal model (Farooqi et al., 2010). Active EAE induced in C57BL/6 mice
(B6 mice) is the animal model selected for all experiments conducted in this project (see
methods section).
In this study, we determined that oral administration of farnesol results in a
decrease of mouse EAE severity, with the decreased disease severity associated with
decreases of macrophages, monocytes, dendritic cells, and CD4+ cells in farnesol
treated mouse spinal cords. Due to farnesol being a positive allosteric GABAA receptor
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modulator, we looked at the possible protective effects of increased intestinal GABA
production by treatment with a modified probiotic. Though early results were
promising, we were unable to repeat the experiment due to difficulties inducing EAE.
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RESEARCH HYPOTHESES
Hypothesis 1#
Oral administration of Farnesol, a positive allosteric GABAA receptor modulator,
will result in decreased disease severity in a EAE murine model of MS, as measured by
clinical scores. It will also result in a decrease in pro-inflammatory immune cell
infiltration of the spinal cord.
Hypothesis 2#
Increasing the levels of intestinal neurotransmitter γ-Aminobutyric acid (GABA)
by treatment with a GABA-producing probiotic will reduce disease severity as measured
by clinical scores in a EAE murine model of MS.
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METHODS
Animal strain and care
Female C57BL/6 mice were obtained from Envigo (Envigo RMS, Inc., Indianapolis,
IN, USA), except in one experiment where another provider was also used (The Jackson
Laboratory, Inc., Bar Harbor, ME, USA). The mice arrived at Eastern Washington
University when they were 8 weeks old and were given time to acclimate before
immunization at 10 weeks. At the time of disease induction, they weighed
approximately 20 g. They were housed in Eastern Washington University’s vivarium in
wire-top cages (46cm x 25cm x 20cm) with bedding. Animals were placed in cages
randomly with 5 animals per cage. The room environment was kept at 22 ± 1°C and 2333% humidity with a 12-hour light/dark cycle. All animals had free access to food and
water. When mice reached an EAE clinical score of 2.5 or higher crushed food soaked in
water was placed in a shallow dish at the bottom of the cage to help facilitate access.
Mice were fed pellet food (Teklad 2018) containing plenty of glutamate for bacterial
synthesis of GABA. All animal care and procedures followed Eastern Washington
University’s Institutional Animal Care and Use Committee (IACUC) policies and approved
protocols.
EAE Induction and Clinical Scoring
Mice were induced with EAE using the Hook KitTM for EAE induction (Hooke
Laboratories, EK-2110). To induce each mouse was given a subcutaneous injection of
250 μg myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) emulsified in complete
Freund’s adjuvant on the flanks at 2 sites on day 0. The same day and 48 hours later the
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mice will receive an intraperitoneal injection of 400ng of Bordetella pertussis toxin (200
μL). In this model, the onset of the disease (where symptoms are first observed) is
typically around days 9-14 and the peak of the disease occurs 3-4 days later.
All mice were monitored for the duration of the experiment, up to 28 days, and
scored daily using the EAE clinical score scale for disease severity. The clinical scores are
based on the degree of paralysis the animal exhibits. 0 is a healthy animal with no
disease; 0.5, a distal limp tail; 1, completely limp tail or isolated weakness of gait without
a limp tail; 1.5, a limp tail and hind limb weakness; 2, unilateral partial hind limb
paralysis; 2.5, bilateral partial hind limb paralysis; 3, complete bilateral hind limb or
partial hind and front limb paralysis; 3.5, complete bilateral hind limb paralysis and
partial front limb paralysis. 5, moribund or dead animal. In accordance with IACUC
policies to minimize undue suffering, mice displaying a score of 3.5 or higher (unable to
right themselves when placed on their sides) for more than two consecutive days were
euthanized. Thereafter the mouse was listed as a 5 (the clinical score for a dead mouse).
Mice were euthanized via carbon dioxide asphyxiation followed by cervical dislocation.
Body weights were measured weekly and expressed as % body weight at time of EAE
induction.
Flow Cytometry
Spinal cord and splenic cells were isolated from mice on day 19 (peak disease)
after EAE induction, to determine the impact of the positive allosteric GABAa receptor
modulator, farnesol, on CNS infiltration. Spinal cords were extracted from the vertebral
cavity by flushing with 1 mL cold sterile phosphate buffer saline (PBS) using a 3-mL
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syringe and 18-gauge needles. The spinal cords were then homogenized and passed
through a 70-µm filter in 1 % bovine serum albumin (BSA) in sterile PBS. They were
washed in PBS and centrifuged at 350xg for 5 minutes, excess liquid was removed, and
the cell pellets were then resuspended in 30mL sterile PBS. They were passed through a
40-µm filter and centrifuged again at 350 x g for 5 mins. Excess liquid was removed, and
the cell pellet was resuspended in 1 mL PBS/1% BSA.
To obtain splenocytes, spleens were homogenized and passed through a 70-µm
filter in sterile PBS. The samples were centrifuged at 350 x g for 5 minutes. Excess liquid
was removed, and the cell pellets were resuspended in 9 ml PBS and 1 mL red blood cell
lysis buffer (Roche Diagnostics GmbH, Mannheim, Germany, cat. # 11 814 389 001).
They were incubated for 10 minutes at room temperature. 50 mL of PBS was added to
each sample. They were passed through a 40-µm filter and centrifuged again at 350 x g
for 5 mins. Excess liquid was removed and the cell pellet was resuspended in 1 mL PBS-1
% BSA.
The spinal cord cell and splenocyte samples were treated with an anti-mouse
CD16/CD32 Fc block this blocks non-specific antibody binding via their Fc regions and
decreases background staining. The samples were then stained with hamster antiCD11b FITC (clone M1/70; BD Biosciences, San Jose, CA, cat. #. 553310), hamster antiCD11c (clone HL3; BD Biosciences, cat. # 553802), and rat anti-mouse F4/80 APC (clone
T45-2342; BD Biosciences, cat. # 566787) to differentiate monocyte/macrophages and
CD11c-positive dendritic cells.
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Samples were stained to detect Tregs using the mouse regulatory T cell staining
kit #1 from eBiosciences (cat. # 88-8111-40; Thermo Fisher Scientific, Waltham, MA).
Which contained the following antibodies: anti-CD4 FITC (RM4-5), anti-CD25 APC
(PC61.5), and anti-mouse/rat Foxp3 PE (FJK-16s). We used rat anti-mouse IgG2a PE as an
isotype control. Samples were analyzed using a BD Accuri C6 flow cytometer (BD
Biosciences) at Washington State University. Data processing was performed with the
FloJo software (FloJo LLC, Ashland, OR).
Lactococcus lactis strains
Strains of Lactococcus lactis used in this study were generated by Dr. Castillo’s
lab at Eastern Washington University. Lactococcus lactis (IL1403) was transformed with
with the pAC plasmid alone, pGh9:ISS1 (Maguin et al., 1996), which contains the gene
for erythromycin resistance (pAC L. lactis) or pAC with the L. lactis (IL1403) genes for
glutamic acid decarboxylase (gadB) and the GABA/glutamate antiporter (gadC)
regulated by the constitutive promoter sequence P5, P2, or P8. Of these differing
promoters, P8 has been identified as the strongest with the greatest transcriptional
efficiency followed by P5 and P2 (Zhu et al., 2015). All L. lactis strains used in this study
were grown at 30◦C without shaking in M17 broth or agar plates (Difco Laboratories,
Detroit, MI) supplemented with 0.5% glucose (GM17) and, in the case of plasmid
containing strains, 5ug/mL erythromycin (ERM GM17). Strains were archived for long
term storage in GM17 media supplemented with 15% glycerol and frozen at -80oC.
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GABA quantitation
A preliminary assay was done with supernatants from each strain of L. lactis (P8L. lactis, pAC-L. lactis, WT-L. lactis, P2-L. lactis, and P5-L. lactis; grown overnight) after
samples were centrifuged to remove cells. The supernatants from the bacterial strain
were tested in triplicate with a GABA-specific enzyme-linked immunosorbent assay
(ELISA) using a GABA ELISA (LDN BA E-2500) at Washington State University, with assay
controls provided by the ELISA kit.
Next, we compared GABA levels produced by the different strains at different
growth phases. To create a growth curve, we took stationary phase bacteria, grown
overnight in GM17 or GM17 ERM broth and diluted 2 replicates of each strain except P2
L. lactis (which due to low GABA production levels was removed) to a OD600 0.2 (optical
density) with GM17 media. After 1 hour of growth, their OD600 levels were tested and
every ½ hour afterwards. Samples were plated to obtain colony forming unit counts
(CFUs) and supernatants were collected and centrifuged (to remove cells) for ELISA’s at
OD600 0.5, 1.0, 1.5 and 2 with two replicates for each strain. At OD600 1.5 there were 8.5
x 108 CFUs/mL of bacteria.
Collected samples along with GM17 media as a control were centrifuged and cell
pellets removed then supernatants were tested with a GABA ELISA kit (AVIVA Systems
Biology, GABA ELISA Kit OKEH02564). The supernatant samples of P8-L. lactis, pAC-L.
lactis, P5-L. lactis, and the GM17 media were all in triplicate. WT-L. lactis was run in
duplicate. The ELISA was run twice with both replicates from the growth curve
experiment and results were combined.
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Treatment for GABAA receptor modulator EAE Experiment
To determine the impact of GABAA receptor modulator farnesol on EAE progression,
we randomly separated 28 mice into 3 treatment groups; a farnesol treatment group
(FOL-EAE; n=10), a vehicle control group (CO-EAE; n=9), and an untreated control group
(U-EAE; n=9). In the FOL group; mice were treated with 100 mg/kg/day FOL (trans-transfarnesol, sigma-Aldrich, cat.#277541) emulsified in corn oil. The vehicle control group
received 100 µL corn oil with no farnesol added. The untreated control group were
induced with EAE with no treatments. Corn oil and farnesol treatments were given by
gavage. Mice were weighed weekly, and treatments were adjusted for mouse weight.
Animals were euthanized on day 19, when the EAE scores are highest in untreated
animals.
Treatment for GAD L. lactis EAE Experiments
Four separate EAE experiments were conducted to determine the impact of
GAD-L. lactis (P8-L. lactis) on EAE severity though only the first worked. In each
experiment, we randomly divided mice into 3 treatment groups: a medium only group
(medium), a pAC-L. lactis group (pAC), and a GAD-L. lactis group (P8). The medium group
was treated with 0.1 mL of GM17 media. The pAC and GAD groups were treated with 5 x
108 CFU a day of their respective strains of bacteria suspended in 0.1 mL of GM17
media. Mice were treated from day 0 to end of the experiment, 5 times a week (Robert
et al., 2014). Treatments were administered via oral gavage. Mice were weighed weekly
and EAE clinical scores were measured daily.
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The P8 and pAC bacterial cultures for treatment were started weekly on GM17
agar plates containing 5 µg/mL erythromycin from -80o C archived strains. Incubated at
30o C, these plates were then used to inoculate overnight cultures of ERM GM17 media.
New ERM GM17 media was made every 3 days and it was stored at ~3oC. Morning
cultures were diluted to OD600 0.2. The bacteria were incubated for 3 hours to OD600 1.5
at 30oC. The ERM GM17 media was removed by centrifugation and the cell pellets were
resuspended in GM17 media to achieve 5X108 CFU per 0.1 mL media. New overnight
cultures were made daily with a dilution of 2 mL broth to 25 µL previous overnight
culture.
Experimental setup for comparing EAE severity between mice providers
To explore the differences in EAE severity between mice from different
providers, we divided 14 C57BL/6 mice from Envigo (Envigo RMS, Inc., Indianapolis, IN,
USA), and 15 Jackson mice (The Jackson Laboratory, Inc., Bar Harbor, ME, USA) into a
naïve group (Envigo-naïve, n=5; Jackson-naïve, n=5) and an EAE induction group (EnvigoEAE, n=9; Jackson-EAE, n=10). EAE clinical scores were taken daily, stool samples and
mouse weights were collected weekly. The experiment lasted for 21 days.
Statistical analyses
Repeated measures and mixed-effect ANOVA followed by Tukey’s multiple
comparison post-hoc tests were used to estimate group differences for EAE clinical
scores, body weights, and body weight changes. Group differences in spinal cord and
spleen immune cell infiltration, disease onset, and disease severity were evaluated using
non-parametric Kruskal-Wallis followed by Dunn’s multiple comparisons tests. GABA
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level means quantified by ELISA were compared by mixed-effect ANOVA followed by
Tukey’s multiple comparison post-hoc test. P values below 0.05 were considered
significant.
RESULTS
Treatment with GABAA receptor modulator reduces immune cell infiltration into spinal
cords at the peak of EAE disease.
Farnesol is an allosteric positive modulator of GABAAR. Due to farnesol’s
reported anti-inflammatory and neuroprotective activities, we sought to determine
whether those protective effects correlated with reduced immune cell infiltration of the
CNS at the peak of the EAE disease (day 19). We observed a significant treatment effect
(p < 0.05) on clinical scores comparing the 3 treatment groups; farnesol (FOL-EAE; n=10),
corn oil (CO-EAE; n=9), and untreated (U-EAE; n=9) (Fig. 1A).
Next, we examined whether the observed protective effects of farnesol
correlated with a reduction in inflammatory immune cell infiltration of the CNS. In
preparation for the flow cytometry analyses, we extracted and processed spinal cords
from each mouse at peak EAE severity on day 19. We discriminated doublets ??and
selected singlets from each spinal cord preparation isolated from the EAE mice (FOLtreated: n=10; vehicle-treated: n=9; untreated: n=9), to ensure only singlets were
counted to avoid false positives. We used a previously published gating strategy (Weiss
et al., 2015).
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The spinal cords’ macrophage subpopulations were compared using the cell
markers; CD11b, CD11c, F4/80 positive and negative markers (Figure 1B). Spinal cords
from mice treated with farnesol had significantly reduced percentages of
granulocyte/monocyte subsets (CD11b+F4/80- and CD11b+F4/80int), as well as monocyte
derived macrophages (CD11b+F4/80+) in their spinal cords in comparison to untreated
and vehicle treated groups (Figure 1C).
We also compared spinal cord CD4+ T cell and Treg frequencies between groups
using the cell markers of CD4+ (CD4+ T cells) and CD25+Foxp3+ (Treg cells). We found
that treatment with farnesol significantly reduced the CD4+ T cell percentage (Figure
2A) and increased the proportion of anti-inflammatory Treg cells within the CD4+ T cell
population (Figure 2B), compared to the untreated and vehicle treated control groups.
We further examined whether these cell frequency results were the same in the
periphery by analyzing immune cell numbers of the spleens taken from the mice used in
the study. Single-cell suspensions were prepared from the mouse spleens and analyzed.
CD4+ T and Treg (CD25+Foxp3+) cell frequencies and proportions did not show
significant differences between groups (Figure 3B). Splenic monocyte/macrophages and
dendritic cell percentages were similarly analyzed. We did not see significant differences
between groups in the percentage of dendritic cells (CD11b+F4/80-CD11c+). We did see a
significant increase in percentage of F4/80int granulocyte/monocytes and monocyte
derived macrophages (CD11b+F4/80+) in farnesol treated mice when compared to
untreated animals. We also saw a significant reduction in F4/80neg
granulocyte/monocytes in cells isolated from corn oil treated (CO-EAE) mice in
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comparison to untreated mice (U-EAE), but there were no significant differences
between CO-EAE and FOL-EAE groups or FOL-EAE and U-EAE (Figure 3A).
The results of our EAE experiment and flow cytometry data confirm our
hypothesis. Farnesol, a positive allosteric GABAAR modulator, confers protection to EAE
mice as shown by a decrease in EAE clinical scores. This protection correlates with a
decrease in pro-inflammatory infiltration of immune cells into their spinal cords. Due to
farnesol being a positive allosteric GABAA receptor modulator, we examined whether
intestinally produced GABA had similar effects on the disease severity of EAE in mice.
Characterization of GAD L. lactis
To examine the effects of intestinally produced GABA, we first characterized the
amount of GABA produced by the modified L. lactis strains. To do this, we preformed
three ELISAs. The first preliminary GABA ELISA (LDN BA E-2500), looking at the GABA
content of supernatants taken from each strain cultured to the stationary growth phase,
showed an increase in GABA levels in supernatants from P8 and P5 GAD- L. lactis, while
P2 had the same GABA levels as the wild type and pAC plasmid L. lactis. Which aligns
with other researchers findings showing increased transcriptional efficiency when using
the P8 promoter, with P5 having slightly less, and P2 the least (Zhu et al., 2015).
We collected supernatants from bacteria grown to various OD600 levels that had
previously been correlated for cell count. These supernatants were tested by ELISA (see
methods). The ELISA was run twice with both replicates from the original experiment
and the results were combined. Unfortunately, the controls provided with the kit did
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not provide a signal that could be quantified, and we were unable to determine a
standard curve for this ELISA. We therefore used the standard curve generated from the
previous ELISA looking at the stationary phase GABA. We did observe a significant
difference between pAC and P8 L. lactis strains at OD 1.5 after controlling for GM17
media (Figure 4B, p = 0.0445). Despite the uncontrollable issues with these ELISAs and
based on the initial results obtained in the first and second set of ELISAs done (Figure 4),
we selected P8 as a strain of L. lactis with enhanced capability to produce GABA for the
in EAE experiments. We determined that P8 L. lactis grown to OD600 1.5 would be used
for these in vivo studies, as the P8 L. lactis supernatant grown to OD 1.5 had the most
GABA production in comparison to others. Furthermore, reverse transcription qPCR
experiments demonstrated that gadB expression in P8 L. lactis strain is consistent with
its increased production of GABA shown in the ELISAs (Castillo, unpublished results).
In vivo effects of GAD L. lactis on EAE
Here we sought to determine if P8 L. lactis producing high levels of GABA would
decrease disease severity in EAE induced mice. We administered P8 L. lactis (GAD L.
lactis), a modified L. lactis strain that produced significantly more GABA compared to L.
lactis with plasmid alone (pAC L. lactis). In our first experiment (GAD L. lactis Experiment
#1) that ran for 25 days, we observed a significant treatment effect on clinical scores
comparing the P8 L. lactis group (n=10) to the L. lactis control (pAC L. lactis; n=10), and
medium control (Medium; n=10) (Figure 5A). We also observed a significant decrease in
weights between mice treated with P8 L. lactis, those treated with pAC L. lactis, and
those treated solely with GM17 medium (Figure 5B). We also saw a significant increase
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in weight comparing the P8 L. lactis group (; n=10) to the pAC L. lactis control (n=10),
and medium control (Medium; n=10) (Figure 5B). Due to the loss of the sickest and
thereby lightest animals, 2 in the medium and 3 in the pAC group, the weights went up
towards the end of the experiment. The distribution of scores showed a clear decrease
in disease severity of P8 mice group with 6 mice not getting sick at all (Figure 5C). Our
multiple attempts to repeat these experiments were met with challenges inducing
disease in EAE mice (Figure 6). To address this issue, we conducted induction
experiments on EAE mice from different animal providers.
Comparing EAE severity in mice from different providers
EAE induction can be easily impacted by numerous factors, including microbiome
diversity. It is possible that the mice from Envigo have a modified intestinal microbiota
because of a change of the microbial environment at the provider. This change in the
microbiota could therefore change their susceptibility to EAE induction.
Due to the issues with the repeat EAE experiments using C57BL/6 mice obtained
from Envigo, we sought to see if mice sourced from a different provider (Jackson) would
have the same level of EAE disease severity and if differences in the microbiome were
responsible. We did not see significant differences between the EAE induction groups
(C57BL/6 Jackson EAE; n=10: and C57BL/6 Envigo EAE; n=9), this may have been due to
the low n number (Figure 7). Yet, we did observe differences in disease severity. The
Jackson group had 8 mice that had to be sacrificed due to high clinical scores (≥3.5 for 2
consecutive days) by the end of the experiment (day 21), while only one mouse from
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the Envigo group had to similarly be sacrificed. Both groups had their first clinical scores
on day 11, with two 0.5 scores in the Envigo group, while the Jackson group had three
0.5 scores and a 1.0 score. We collected stool samples and have sent them to be
analyzed. We hope to farther explore the possibility of differences in intestinal
microbiota of mice between the two providers once we receive the results of the
analysis. In future experiments with EAE, we plan to use Jackson mice due to their
increased susceptibility to the EAE induction.
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DISCUSSION
Multiple sclerosis is a neuroinflammatory disease of the central nervous system
(CNS). Although the origins of the disease remain to be deciphered, it has been
proposed that environmental factors, as well as genetics are all involved in disease
initiation and progression. Unfortunately, although several drugs for the treatment of
the disease have emerged over the last decades, no definitive cure exists. Most
treatments for MS are expensive, lack effectiveness, and/or have dangerous side
effects. Novel strategies for dealing with MS disease progression are needed. Despite
the advances in the understanding of the etiology but also the pathogenesis and
progression of the disease, many questions about MS remain unanswered. As described
in the introduction, one striking feature of the disease is the unbalanced levels of GABA
observed in MS patients. Similarly, recent findings indicate that the composition of the
gut microbiota plays a significant role in modulating the immune, metabolic and
neuronal pathways, including GABA production and function. The goal of this study was
to look at the effects of intestinal GABAA receptor activation on murine EAE.
In our investigation, we first examined the effects of farnesol, a positive
allosteric GABAA receptor modulator. Farnesol had been previously described as an antiinflammatory, anti-oxidative, and neuroprotective natural compound, produced by
many organisms. Prior laboratory experiments have identified Farnesol as a potential
novel treatment for CNS inflammatory demyelination diseases, such as MS.
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In the experiments shown here, we observed a significant decrease in disease
severity between farnesol treated animals and untreated animals. Using flow cytometry,
we were able to correlate this decrease in disease severity to a decrease in immune cell
infiltration of the CNS when the severity of the disease is at the highest level (peak of
disease). Previous experiments on farnesol by Christina Ramelow and Lacey Sell,
graduate students from our lab, identified the protective effects of farnesol in the EAE
model. They found through experiments with the same three treatment groups we
used; (FOL-EAE, n =18; CO-EAE, n = 23; U-EAE, n = 24), a significant decrease in EAE
score severity between the farnesol treated group and the others (p < 0.001) from
induction (day 0) to the end of treatment (day 26). They also found that disease onset
on average was significantly delayed in farnesol treated mice (14.9 ± 0.54) in
comparison to untreated mice (12.6 ± 0.37; p = 0.0004). Flow cytometry analysis of the
spinal cords of surviving treated and untreated EAE mice at the end of the experiment
(day 26) (untreated: n = 4; vehicle-treated: n = 9; FOL-treated: n = 8) showed a
significant reduction of infiltrated CD4+ T cells in comparison to the untreated EAE mice.
Unfortunately, due to high animal loss of the most severe EAE animals by day 26 in their
experiments, the sickest animals were not included. We attempted the same
experiment using flow cytometry results from mice taken at the peak of disease (day
19), allowing a greater n number, due to a decrease in animal loss from severe EAE later
in the disease.
The results provided in this thesis were obtained not on surviving animals but on
EAE mice during full blown disease, providing even more relevant information regarding
33

the effects of farnesol, a GABAAR modulator, correlating reduced immune cell
infiltration with disease protection. Furthermore, the results shown in this thesis
provide evidence that the oral treatment with farnesol promotes the accumulation of
Tregs in the CNS of EAE mice. As described in the introduction, Tregs are a key antiinflammatory cell subpopulation of T cells associated with protection against
inflammatory and autoimmune disorders, such MS. We describe a decrease in CNS of
inflammatory immune cell percentage (granulocyte/monocyte, monocyte derived
macrophage, and CD4+ T cell percentages) in the spinal cords of mice treated with
farnesol, in comparison to untreated and vehicle treated groups. We also saw an
increase in the percent of anti-inflammatory Treg cells. It may be tempting to conclude
that farnesol works through Treg accumulation in the CNS. As a limitation of the study,
we must remember that these differences are based on cell percentages not absolute
cell count, and the small number of cells counted through flow cytometry. As we
observed no corresponding increase in peripheral (spleen) Treg numbers (Figure 3),
farnesol protection may not be associated with Treg mediated immunomodulation. The
decrease in inflammatory immune cells were not seen in the periphery either. This
observation could imply that treatment of farnesol does not cause immunodeficiency.
Simultaneously, it implies that the mechanism by which farnesol is protective against
CNS inflammatory demyelination needs to be determined.
The difficulty with ascribing this effect to GABAA receptor modulation, is that
farnesol’s anti-inflammatory and neuroprotective properties may be caused through
mechanisms other than GABAA receptors. Farnesol is known to block Ca2+ channels (Luft
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et al., 1999; Beedle and Zamponi, 2000) and intraneuronal Ca2+ overload has been linked
to MS pathogenesis (Kattimani and Veerappa, 2018; Verma et al., 2018). Farnesol is also
a potent antioxidant and has been shown to decrease pro-inflammatory cytokine
secretion. These or other mechanisms may be the underlying reason for the
neuroprotective activity of the orally administered farnesol, not activation of GABAA
receptors. To further elucidate the specific effect of intestinal GABAA receptor
activation, we used modified L. lactis strains provided by Dr. Castillo’s lab at EWU as a
mechanism to increase intestinal GABA levels.
The first step of the validation of the probiotic L. lactis constructs was to
determine the production of GABA by the genetically modified strains. We performed
three ELISAs to quantify the amount of GABA produced by the strains. The first ELISA
used supernatant from strains grown till they saturated the media in their stationary
phase. Since they were all grown to the same stage, we were able to compare between
strains to a degree, and although we observed a trend to increased production, no
significance was observed. The colony forming units (CFU) of the original bacterial
samples used for the ELISA analysis were not collected. Thus, and despite the positive
ELISA outcome, with a standard curve (correlation of 0.9887 and R squared 97.75%). we
were unable to normalize GABA levels with CFU of bacteria per volume (CFU/ml). The
lack of CFU/ml normalization could explain why no significance was achieved. GABA
production can also vary by growth phase as you see with the second set of ELISAs. The
findings from this ELISA align with other researchers findings that the P8 promoter has
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the greatest transcriptional efficiency, followed by the P5, and of the series of
promoters the P2 promoter is the least efficient (Zhu et al., 2015).
For the next GABA quantification experiments, the ELISA were performed with
supernatants taken from strains grown from an OD600 of 0.2 for the same amount of
time, with known CFU levels (based on growth curves determined as described in the
methods section). The GABA characterization by ELISA was then performed using a
different kit from (AVIVA Systems Biology, GABA ELISA Kit OKEH02564). Unfortunately,
the standard controls provided with the kit did not provide a signal that could be
quantified and were oversaturated. We were unable to determine a standard curve for
this ELISA. We used the standard curve generated from the previous ELISA on stationary
phase substrates to generate approximate GABA levels. Strain comparison showed a
significant difference between pAC and P8 L. lactis strains at OD 1.5. Furthermore, RTqPCR data indicate that the P8 L. lactis strain expresses gadB (encoding for glutamic acid
decarboxylase responsible for synthesizing GABA) at a significantly higher level than wild
type L. lactis and pAC (Castillo, unpublished results). Additional commercially available
GABA ELISAs will need to be used to validate our preliminary results, normalizing them
to CFU/ml of cultured L. lactis.
GABA produced naturally by the wild-type strain IL1403 changes depending on
the environment. The expression levels of gadBC genes in Lactobacillus brevis have been
found to increase in response to moderately acidic environments (pH 5.2), while
declining in neutral environments (pH 6.8). Expression is highest in the exponential
growth phase, while sharply declining once the bacteria enter stationary growth phase.
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Expression of gadBC can also change depending on temperature (Lyu et al., 2018; Gong
et al., 2019). The exact amount of GABA produced by our strains would vary depending
on the intestinal environment of the mice. We attempted to control for this as well as
for non-GABA related effects by treating one group of mice with an L. lactis strain that
did not contain the extra gadCB genes. As the engineered strains express their extra
copies of gadCB constitutively; those extra copies are not under the endogenous
promoter controls. Another variable is the ability of L. lactis to survive. In the first hour
of ingestion, L. lactis decreases sharply due to poor survival in low pH, pH 2 is
considered lethal (Tan et al., 2019). Stomach pH can vary widely, depending on how
recently and what the subject ate, as well as how close to the mucosa it is measured.
Humans range from pH 1-2 in the gastric lumen to pH 6-7 at the mucosal surface (Hunt
et al., 2015). All these variables may result in differing levels of intestinal GABA
production in treated mice. Future projects/experiments from the lab will attempt to
encapsulate the GABA-producing GAD L. lactis in biodegradable microparticles that
facilitate their survival through their gastrointestinal tract journey.
One of the most limiting stumbling blocks of our project was that in our GAD L.
lactis in vivo experiments, the severity of EAE disease was reduced in mice. Even the first
experiment, where a significant treatment effect was observed, there were mice from
each group that did not show clinical scores (6 in P8-treated, 3 in pAC-treated, 2 in
medium-treated groups). At first, we thought the reduced severity may have been the
result of increased chronic stress due constant handling of the mice (stool collection,
weights, daily scores, and oral treatments by gavage). Chronic stress before EAE onset,
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can lead to a decrease in EAE disease severity, but if exposed to chronic stress later in
the course of EAE it exacerbates the disease (Correa et al., 1998). Though some studies
have shown contradictory results (Gerrard et al., 2017). Reducing human contact did not
affect EAE severity in our studies.
An alternative to the stress hypothesis as a modifier of EAE severity is the
microbiota and the origins of the mice used for the studies. Previous experiments, and
the studies shown in figures 1-3 with farnesol, used the same mice strain, mouse
provider, EAE induction kit, and living situation (EWU vivarium), as well as similar
handling levels. However, no problems with EAE induction and disease progression were
observed. EAE induction can be easily impacted by numerous factors, including
microbiome diversity. The microbiome is needed for the appropriate development of
the immune system (Kiyono et al., 1982; Wannemuehler et al., 1982; Sudo et al., 1997)
and numerous studies point to a link between microbiome dysbiosis and MS (OchoaRepáraz et al., 2018; Kohl et al., 2020). Moreover, previous studies have shown that
mouse breeding conditions significantly affect the composition of mouse microbiota,
with the presence or absence of bacterial species associated with the induction of Th17
proinflammatory responses, such as segmented filamentous bacteria SFB (Ivanov et al.,
2009). SFB monocolonization has been shown to restore EAE susceptibility in germ-free
mice by increasing proinflammatory Th17 cell function (Lee et al., 2011). Due to the
coronavirus pandemic of 2020, numerous lab protocols changed worldwide, with
modifications in numbers and age of mice available, it is possible that the mice received
harbor a modified microbiota because of a change of the microbial environment at the
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provider. The change in the microbiota could therefore change their susceptibility to
disease, as the microbiota is key to modulating disease severity.
To test whether the problem was our vivarium or a difference in the providers
mice, we compared EAE induced C57BL/6 female mice from one commercial provider
(Envigo) to C57BL/6 mice from a second provider (Jackson Laboratory), independent of
treatments. We observed a difference, though it was not statistically significant possibly
due to the low n number. However, 8 mice from Jackson died or had to be euthanized
due high disease scores (>3.5 for two consecutive days) while only one mouse was
euthanized due high score in the Envigo group. Overall, the incidence of the disease was
high, as expected for C57BL/6 mice. This could imply that the reduced incidence and
severity of EAE is not due to changes in EWU’s vivarium’s environment. We hope to
farther explore the possibility of differences in the microbiome causing changes in EAE
severity between the same mouse strains from different providers. We have collected
stool samples from all mice and sent them for microbiota sequencing and analysis.
While we were able to show a decrease in EAE severity in mice treated with
farnesol, a positive allosteric GABAA receptor modulator, it is not clear if those effects
were due to the activation of the GABAA receptor or due to one of farnesol’s other
effects. The difficulties in inducing EAE prevented us from confirming our hypothesis
that intestinal GABAA receptor activation by intestinally produced bacteria ameliorates
the progression of murine EAE. It may be possible in future studies to repeat this
experiment with Jackson mice and have stronger EAE disease induction.
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TABLES AND FIGURES
Table 1 Most common FDA approved treatments for MS

FDA approved Treatments for Multiple Sclerosis
Injectable Medications
Chemical Name Limitations
Common Side
Effects
Interferon beta- Can lead to flu- Flu-like symptoms,
1a
like symptoms injection site pain
and inflammation
Interferon beta- Can lead to flu- Flu-like symptoms
1b
like symptoms injection site pain
and inflammation
skin breakdown
low white blood
cell count
Glatiramer
Weakens
Injection site
acetate
immune
inflammation and
system
pain, flushing,
shortness of
breath, rash, and
chest pain
Oral Treatments
Teriflunomide
Weakens
Headache, hair
Immune
thinning, diarrhea,
system
nausea, abnormal
liver tests
Fingolimod
Weakens the
Headache, flu,
Immune
diarrhea, back
system
pain, abnormal
liver tests,
Bradycardia
sinusitis,
abdominal pain,
pain in extremities,
cough
Cladribine
Weakens the
Upper respiratory
immune
infection,
system
headache, low

Mechanism of
Action
Synthetic
Interferon beta
an antiinflammatory
cytokine
Synthetic
Interferon beta
an antiinflammatory
cytokine
Kills immune
cells

Dampens
Immune System
Stops T and B
cells from
leaving the
lymph nodes
(Mehling et al.,
2008).
Kills T and B cells
by interfering
with DNA
synthesis and
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Dimethyl
fumarate

Weakens
immune
System
Intravenous Infusion Treatments
Alemtuzumab
Weakens
Immune
System
Can lead to
serious
complications
with lungs,
thyroid, and
blood

Ocrelizumab

Weakens
Immune
System

Natalizumab

Weakens
immune
system
Increases risk
of progressive
multifocal
leukoencephal
opathy (PML)

Other treatments
Hematopoietic Expensive
stem cell

white blood cell
count

repair
(Alroughani et
al., 2019)

Flushing and
gastrointestinal
issues

Dampens
immune system

Flu like symptoms, Kills T and B cells
rash, increased risk (Alroughani et
of infections, hives, al., 2019)
itching, thyroid
gland disorders,
pain in joints,
extremities and
back, diarrhea,
vomiting, flushing
and infusion
reactions
Infusion reactions
which in rare
instances may be
life-threatening;
increased risk of
infections; possible
increased risk of
cancer
Flue like
symptoms,
increased risk of
infection,
depression, pain in
extremity,
abdominal
discomfort,
diarrhea, and rash

It is an antibody
that targets B
cells (Alroughani
et al., 2019)

Side effects from
chemotherapy

Uses
chemotherapy

It is a
monoclonal
antibody that
targets T cells
preventing them
from activating
and migrating to
sites of
inflammation
(Rice et al.,
2005).
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transplantation
(HSCT)

Requires
chemotherapy

to kill off
immune cells
and replaces
them with the
patients’
hematopoietic
stem cells from
the their bone
marrow
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Figure 1: Oral treatment of FOL decreases mouse EAE clinical scores and macrophage
infiltration of the CNS
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Figure 1. Oral treatment of FOL decreases mouse EAE clinical scores and macrophage
infiltration of the CNS. Granulocyte/monocyte subsets (CD11b+F4/80- and
CD11b+F4/80int), as well as monocyte derived macrophages (CD11b+F4/80+) were
measured by flow cytometry at day 19 post-EAE induction in untreated EAE mice (UEAE; n = 9), corn oil vehicle control mice (CO-EAE; n = 9), and farnesol treated mice (FOLEAE; n = 10) mice. Data are presented as mean ± 1 SEM. A. EAE scores from EAE
induction, day 0, until peak of disease, day 19 (*, p< 0.05, **, p < 0.01). B. The gating
strategy used to identify CD11b+F4/80- (granulocyte/monocytes), CD11b+F4/80int
(granulocyte/monocytes), CD11b+F4/80+ (monocyte-derived macrophages),
CD11b+F4/80-CD11c+ (monocyte-derived dendritic cells) subpopulations, and CD4+ T
cells C. Percentage of CD11b+F4/80-, CD11b+F4/80int, and CD11b+F4/80+ subpopulations
(**, p < 0.01; ***, p < 0.001). D. Percentage of CD11c+ cells in gated CD11b+F4/80- cells
(**, p < 0.01). The percentages displayed in the plots signify the positive cell frequency
in pre-gated populations.
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Figure 2: CD4+ T cell frequency decreases and the proportion of Treg cells increase in
FOL treated EAE mice

Figure 2: CD4+ T cell frequency decreases and proportion of Treg cells increase in FOL
treated EAE. Flow cytometry measurements show the percentages of CD4+ T cells and
CD4+ T cells expressing CD25+Foxp3+ (Tregs) taken from mouse spinal cords at day 19
post-EAE induction in U-EAE (n = 10), CO-EAE (n = 9), and FOL-EAE (n = 10) mice. Data
are presented as mean ± 1 SEM. A. Percentage of CD4+ T cells in singlets and total of the
spinal cords. B. Percentage of CD25+Foxp3+ cells in gated CD4+ T cells. (*, p < 0.05; **, p
< 0.01).
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Figure 3: FOL treatment modifies splenic monocyte/macrophage frequencies in EAE
mice, but not splenic CD4+ T cell infiltration

Figure 3: Oral treatment with FOL modifies the splenic monocyte/macrophage frequencies in
mice at the peak of EAE but does not change splenic infiltration by CD4+ T cells or dendritic
cells. Splenic cell analyses were performed by flow cytometry at day 19 (end of treatment) in UEAE (n = 10), CO-EAE (n = 9), and FOL-EAE (n = 10) mice. A. Percentages of F4/80neg
granulocyte/monocytes, F4/80int granulocyte/monocytes, monocyte-derived macrophages, and
monocyte-derived dendritic cells subpopulations in splenic population (individual data and mean
± 1 SEM). B. Percentages of CD4+ T cells in total splenic population, CD25+Foxp3+ cells in
gated CD4+ T cells, and CD25+Foxp3+CD4+ T cells in total splenic population.

46

Figure 4: Increased GABA production in P8 L. lactis strain at OD 1.5
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Figure 4: ELISA test results showing increased GABA levels in supernatants from P8 L.
lactis compared to supernatants from wild type L. lactis (WT), pAC L. lactis, and P5 L.
lactis. ELISA results for GABA levels of both replicates of supernatants taken from
cultures grown to OD600 0.5, 1.0, 1.5, and 2.0 after controlling for GM17 media GABA
levels. The experiments were conducted on 2 separate occasions with 3 replicates per
experiment.
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Figure 5: GAD L. lactis experiment shows P8 L. lactis strain decreases EAE disease
severity

A.

C.

B.

Day 19 after EAE induction

Day 25 after EAE induction
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Figure 5: GAD L. lactis oral administration of P8 L. lactis strain decreases EAE disease
severity (P8 L. lactis, n =10; pAC L. lactis, n = 10; Medium, n = 10). A. Clinical severity
score from induction (day 0) to end of treatment (day 25) (treatments 5X week). B.
Percent body weight vs. initial body weight. Data are presented as mean ±1 SEM. C. EAE
clinical score distribution at peak of disease (day 19) and end of experiment (day 25).(*,
p < 0.05, ***, p < 0.001).
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Figure 6: Mice failed to develop EAE in repeat GAD L. lactis Experiments

3.0

Medium (n=10)
pAC (n=9)
P8 (n=10)

EAE clinical scores

2.5
2.0
1.5
1.0
0.5
0.0

0

2

4

6
8
10 12 14 16
Days after disease induction

18

Figure 6: Mice failed to develop EAE in GAD L. lactis repeat EAE experiments. Above is
the results of one of 3 repeat experiments. In all of them the mice were did not develop
enough EAE severity to use the experiment.
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Figure 7: Differential EAE disease severity seen between C57BL/6 mice from different
providers

A.

B.

C.

D.

Figure 7: Differential EAE disease severity seen between C57BL/6 mice from different
providers. C57BL/6 female Envigo mice (Envigo-EAE, n=9) and C57BL/6 female Jackson
mice (Jackson-EAE, n=10) were induced with EAE with no treatments, EAE clinical scores
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were collected daily, and mice were weighed weekly. Naïve C57BL/6 mice from each
provider were used as controls (Envigo-naïve, n=5; Jackson-naïve, n=5). A. Clinical
severity score from induction (day 0) to the end of experiment (day 25) B. Percent body
weight vs. initial body weight. C. Disease severity comparing the two EAE induction
groups (C57BL/6 Jackson EAE; n=10: and C57BL/6 Envigo EAE; n=9) D. Day of disease
onset comparing the two EAE induction groups. No significant differences between the
EAE induction groups (C57BL/6 Jackson EAE; n=10: and C57BL/6 Envigo EAE; n=9) were
observed.
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